跳至主要内容
临床试验/NCT05083429
NCT05083429已完成不适用

Replication of the POET-COPD Trial in Healthcare Claims Data

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 8,716 人开始时间: 2020年9月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
8,716
试验地点
1
主要终点
Time to first COPD exacerbation

研究概览

简要总结

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

详细描述

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
40 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater or equal than 40: days [0,0]
  • Diagnosis of COPD: days [-All Data, 0]
  • History of at least 1 COPD exacerbation within the past year requiring treatment with antibiotics and/or systemic steroids and/or requiring hospitalization: days [-365, -28]

排除标准

  • Patients with 3 diagnosis of asthma: days [-180, 0]
  • Patients with current severe cardiovascular disorders (Heart Transplantation, LVAD/Implantable heart, Pulmonary hypertension/other pulmonary disease) and use of systemic corticosteroid medication at unstable doses: days [-365, 0]
  • Patients with any respiratory infection (Acute respiratory infections, pneumonia and influenza) or COPD exacerbation: days [-28, 0]
  • Exclude use of salmeterol or tiotropium containing inhaler use [-180, 0]

研究组 & 干预措施

Salmeterol inhaler

Reference group

干预措施: Salmeterol (Drug)

Tiotropium

Exposure group

干预措施: Tiotropium (Drug)

结局指标

主要结局

Time to first COPD exacerbation

时间窗: [Time Frame: To censoring or study completion, up to 365 days]

Time to first COPD exacerbation

次要结局

  • All-cause death([Time Frame: To censoring or study completion, up to 365 days])

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shirley Vichy Wang

Assistant Professor

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验

Replication of the POET-COPD Trial in Healthcare... | 临床试验